APA (7th ed.) Citation

Okada, N., Taro, S., Ando, H., Nakamura, S., Goda, M., Abe, M., . . . Ishizawa, K. (2023). Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor. Clinical pharmacology in drug development, 12(8), 826-831. https://doi.org/10.1002/cpdd.1225

Chicago Style (17th ed.) Citation

Okada, Naoto, Shimizu Taro, Hidenori Ando, Shingen Nakamura, Mitsuhiro Goda, Masahiro Abe, Takashi Kitahara, Tatsuhiro Ishida, and Keisuke Ishizawa. "Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor." Clinical Pharmacology in Drug Development 12, no. 8 (2023): 826-831. https://doi.org/10.1002/cpdd.1225.

MLA (9th ed.) Citation

Okada, Naoto, et al. "Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated‐Granulocyte Colony‐Stimulating Factor." Clinical Pharmacology in Drug Development, vol. 12, no. 8, 2023, pp. 826-831, https://doi.org/10.1002/cpdd.1225.